Brokers Offer Predictions for ARCT Q3 Earnings

Key Points

• HC Wainwright estimates Arcturus Therapeutics will report a Q3 2025 earnings per share of ($1.46) and has set a price target of $60.00 for the stock, maintaining a "Buy" rating.
• After a recent earnings report, Arcturus beat analysts' expectations with a reported EPS of ($0.34), and revenue of $28.30 million compared to estimates of $17.64 million.
• Eight analysts currently rate Arcturus Therapeutics as a "Buy," reflecting strong institutional support with 94.54% of shares held by hedge funds and other institutional investors.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a research note issued to investors on Thursday, September 4th. HC Wainwright analyst A. Fein expects that the biotechnology company will earn ($1.46) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Arcturus Therapeutics' Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($3.89) EPS, Q1 2026 earnings at ($1.08) EPS, Q2 2026 earnings at ($1.16) EPS, Q3 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.32) EPS, FY2026 earnings at ($4.78) EPS, FY2027 earnings at $0.94 EPS, FY2028 earnings at $7.84 EPS and FY2029 earnings at $14.51 EPS.

A number of other equities analysts have also weighed in on ARCT. Leerink Partners reduced their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a research note on Friday, August 22nd. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Finally, Citigroup reissued a "buy" rating and set a $49.00 price target (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $50.57.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded down $0.72 during midday trading on Monday, hitting $17.32. 644,225 shares of the company traded hands, compared to its average volume of 516,680. The company has a market cap of $470.41 million, a PE ratio of -7.77 and a beta of 2.39. The company's 50-day simple moving average is $15.38 and its 200-day simple moving average is $13.42. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. The business had revenue of $28.30 million for the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Kennedy Capital Management LLC boosted its position in Arcturus Therapeutics by 4.9% during the second quarter. Kennedy Capital Management LLC now owns 11,674 shares of the biotechnology company's stock worth $152,000 after purchasing an additional 544 shares in the last quarter. Osaic Holdings Inc. grew its stake in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 738 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Arcturus Therapeutics by 5.0% in the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 883 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Arcturus Therapeutics by 4.5% in the 1st quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company's stock worth $248,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 9.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock worth $156,000 after acquiring an additional 1,232 shares in the last quarter. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.